{"disease":{"id":"amyloid-light-chain-amyloidosis","name":"amyloid light chain amyloidosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05652335","title":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT07081646","title":"A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":91,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05839626","title":"A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06455748","title":"Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Yongyong MA","has_results":false},{"nct_id":"NCT05486481","title":"Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Alfred Chung, MD","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}